46 results
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:19pm
, suspensions or termination of clinical trials by the applicable institutional review board or independent ethics board responsible for overseeing the study
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:18pm
.
[Reserved]
Item 16A.
Audit Committee Financial Expert
Item 16B.
Code of Ethics
Item 16C.
Principal Accountant Fees and Services
Item 16D.
Exemptions from … could result in regulatory sanctions and serious harm to our reputation. We have adopted a Code of Business Conduct and Ethics (“Code of Conduct
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:15pm
or terminate a study; delays, suspensions or termination of clinical trials by the applicable institutional review board or independent ethics board
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:12pm
, suspensions or termination of clinical trials by the applicable institutional review board or independent ethics board responsible for overseeing the study
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:11pm
.
[Reserved]
Item 16A.
Audit Committee Financial Expert
Item 16B.
Code of Ethics
Item 16C.
Principal Accountant Fees and Services
Item 16D.
Exemptions from … could result in regulatory sanctions and serious harm to our reputation. We have adopted a Code of Business Conduct and Ethics (“Code of Conduct
424B3
biuj3qj5me zbte
13 Jun 24
Prospectus supplement
4:10pm
6-K
EX-99.2
1s59ftco zo
16 May 24
Condensed Interim Consolidated Financial Statements
6:45pm
6-K
EX-99.2
t1y9c7a gjsbkgn
15 Nov 23
Condensed Interim Consolidated Financial Statements
9:30pm
424B3
0zqnst486d
25 Aug 23
Prospectus supplement
6:00am
424B3
8ha4vndjp3x58mlpwibt
25 Aug 23
Prospectus supplement
6:00am
6-K
EX-99.2
upa5rudfdsxit4e
15 Aug 23
Condensed Interim Consolidated Financial Statements
6:00am
6-K
EX-99.2
lus8ycw6dv
30 May 23
Notice of Annual & Special Meeting of Shareholders
7:00am
6-K
EX-99.2
q5r8n3cum872u2cura
16 May 23
Condensed Interim Consolidated Financial Statements
9:32am
6-K
EX-99.3
7bnp2vm
3 Apr 23
Consolidated Financial Statements
6:05am